Inhibrx Biosciences, Inc.INBX
Inhibrx Biosciences, Inc. Income Taxes Disclosure
INCOME TAXES
The components of the Company’s income (loss) before income taxes are as follows (in thousands):
| YEAR ENDED DECEMBER 31, | |||||||||||
| 2025 | 2024 | ||||||||||
United States | $ | (140,053) | $ | 1,687,574 | |||||||
Foreign | — | — | |||||||||
Loss provision for before income taxes | $ | (140,053) | $ | 1,687,574 | |||||||
The components of income tax expense were as follows for the years ended December 31, 2025 and December 31, 2024, respectively (in thousands):
| YEAR ENDED DECEMBER 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Current: | |||||||||||
| State | $ | 2 | $ | 2 | |||||||
| Total current | $ | 2 | $ | 2 | |||||||
The provision for the years ended December 31, 2025 and December 31, 2024 was related to state income taxes.
The Company made no material income tax payments during 2025 for Federal, state, and foreign jurisdictions.
The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on January 1, 2025 on a prospective basis. As a result, the Company's rate reconciliation for 2025 is presented in accordance with the new disclosure requirements, while the reconciliation for 2024 continues to be presented under disclosure requirements in effect for that period.
A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):
| YEAR ENDED DECEMBER 31, | |||||||||||
| 2025 | |||||||||||
Federal income taxes at 21% | $ | (29,411) | 21.0 | % | |||||||
State taxes, net of federal benefit (1) | 1 | — | % | ||||||||
Change in valuation allowance | 29,552 | (21.1) | % | ||||||||
Other | (140) | 0.1 | % | ||||||||
Effective tax rate | $ | 2 | — | % | |||||||
(1) 50% or more of our state tax provision relates to the California state jurisdiction.
A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09):
| YEAR ENDED DECEMBER 31, | |||||
| 2024 | |||||
| Expected income tax expense at federal statutory rate | $ | 354,390 | |||
| State income tax expense, net of federal benefit | 10,106 | ||||
| Permanent items | 6,842 | ||||
| R&D credits | (28,602) | ||||
| Unrecognized tax benefits (FIN 48) | (4,651) | ||||
Elimination of deferred tax assets and liabilities upon Transaction with Acquirer | 195,694 | ||||
Non-taxable gain related to Transaction with Acquirer | (410,226) | ||||
336(e) election | 665 | ||||
| Valuation allowance | (124,216) | ||||
| Income tax expense | $ | 2 | |||
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The components of net deferred tax assets and liabilities are as follows (in thousands):
| AS OF DECEMBER 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Deferred tax assets | |||||||||||
| Net operating loss carryforward | $ | 40,276 | $ | 4,726 | |||||||
Section 174 research and development capitalization | 8,183 | 15,718 | |||||||||
| Stock compensation | 2,355 | 809 | |||||||||
| Accrued expenses | 1,427 | 893 | |||||||||
| Operating lease liabilities | 1,414 | 1,776 | |||||||||
| Intangibles | 46 | 56 | |||||||||
| Property and equipment | 18 | — | |||||||||
| Other | 2 | 5 | |||||||||
| Gross deferred tax assets | 53,721 | 23,983 | |||||||||
| Less: Valuation allowance | (52,508) | (21,789) | |||||||||
| Total deferred tax assets after valuation allowance | 1,213 | 2,194 | |||||||||
| Deferred tax liabilities | |||||||||||
| Property and equipment | — | (575) | |||||||||
| Operating lease right-of-use assets | (1,213) | (1,619) | |||||||||
| Total deferred tax liabilities | (1,213) | (2,194) | |||||||||
| Net deferred tax assets (liabilities) | $ | — | $ | — | |||||||
In connection with the Separation, the Former Parent retained all rights associated with the unused federal and state NOLs and research tax credit carryforwards as of the date of the transaction to offset its future taxable income. As of December 31, 2025, the Company had unused federal and state NOL carryforwards of approximately $183.1 million and $32.8 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2034 if not utilized.
The utilization of NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. Following the Separation, the Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company may incur ownership changes in the future. If an ownership change has occurred, the Company’s ability to use its NOL carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2025. Such objective evidence limits the ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, as of December 31, 2025, a valuation allowance of $52.5 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be
given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company’s projections for growth.
The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):
| AS OF DECEMBER 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Beginning balance | $ | — | $ | 4,651 | |||||||
Increases (decreases) related to current year tax positions | — | (4,651) | |||||||||
| Ending balance | $ | — | $ | — | |||||||
As of December 31, 2025, the Company did not have any gross unrecognized tax benefits. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December 31, 2025 or December 31, 2024, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2025 and December 31, 2024 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced.
The Company is subject to income taxes in the United States and various state jurisdictions. Following the Separation, the Company’s tax years from 2024 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.
On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law. The OBBBA includes significant changes to U.S. tax and related laws. Some of the provisions of the OBBBA affecting corporations include the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, or TCJA, modifications to the Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income international tax provisions, an increase in the limit of the deduction of interest expense to 30% of earnings before interest, taxes, depreciation, and amortization, and reinstatement of 100% bonus depreciation deduction from the TCJA for eligible property acquired after January 19, 2025. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA’s financial reporting implications have been recognized in our income tax provision for 2025. The incorporation of these effects resulted in no material impact on the Company’s effective tax rate.
Free Sentinel
Track for freeWant the next Inhibrx Biosciences, Inc. income taxes disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Inhibrx Biosciences, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 19, 2026 | Showing above |
| 2024 | Mar 17, 2025 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.